SEC Form 4 · accession 0001179110-16-026666
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael A. Sherman
Officer — President, CEO and CFO · Director
Period of report
Jun 16, 2016
Accepted (ET)
Jun 20, 2016 · 5:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 16, 2016 | A | 10,000 | $0.00 | A | 136,360 | D | |
| Common Stock | holding | — | — | — | 19,919 | I | By Sherman Investors, LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $3.68 | Jun 16, 2016 | A | 60,000 | A | — | Jun 16, 2026 | Common Stock | 60,000 | 60,000 | D |
Explanation of responses
- F1Represents restricted stock units that will vest and be paid 1/4 annually over a period of 4 years beginning on June 16, 2017, in the form of one share of common stock for each restricted stock unit.
- F2Includes 1,388 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on June 15, 2016.
- F3Shares subject to the option vest 1/4 annually over a period of 4 years beginning on June 16, 2017.